KalVista Pharmaceuticals beats Q4 topline estimates (NASDAQ:KALV)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...